
Keywords: درمان پیشگیرانه; Atypical hemolytic uremic syndrome (aHUS); prophylactic therapy; plasmapheresis; eculizumab; living donor; kidney transplantation; recurrence; complement; mutation; variant; thrombotic microangiopathy (TMA); drug costs; end-stage renal disease (ESRD); cas